Peptide LibraryTeduglutide
Teduglutide is an FDA-approved GLP-2 analog. Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 3752.1 g/mol
- Half-life
- —
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Recombinant analog of glucagon-like peptide-2 approved for adults and children with short bowel syndrome who depend on parenteral support. It is the only approved peptide acting specifically on intestinal mucosal growth.
Research evidence
- Regulatory review (FDA label)2 reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Teduglutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Teduglutide dosage evidence
Teduglutide has an FDA-approved human dosage. Gattex for short bowel syndrome in adults and children aged 1 and over who depend on parenteral support is 0.05 mg/kg once daily under the skin. With an eGFR under 60 mL/min/1.73 m² the dose is 0.025 mg/kg once daily.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.05 mg/kg once daily (0.025 mg/kg with reduced kidney function) |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | Continuous, with colonoscopy and lab checks |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Gattex, short bowel syndromeFDA-approved label · FDA prescribing information | Adults and children aged 1 year and older with short bowel syndrome who depend on parenteral support | 0.05 mg/kg | Subcutaneous, rotating abdomen, thighs or arms | Once daily | Continuous | Treatment of short bowel syndrome | GATTEX (teduglutide) for injection — FDA prescribing information, DailyMed |
| FDA label — Gattex, reduced kidney functionFDA-approved label · FDA prescribing information | Adults and children with moderate or severe renal impairment or end-stage renal disease (eGFR under 60 mL/min/1.73 m²) | 0.025 mg/kg | Subcutaneous | Once daily | Continuous | Treatment of short bowel syndrome | GATTEX (teduglutide) for injection — FDA prescribing information, DailyMed |
Where sources disagree
- Gattex is a powder that is mixed with the supplied diluent before each injection; it is a prescription kit, not a vial product in this library's shop.
- The label requires a colonoscopy and upper GI endoscopy in adults (fecal occult blood testing in children) within 6 months before starting, with polyps removed. Its warnings list acceleration of neoplastic growth, and say to stop Gattex if an intestinal malignancy is found.
Sequence & molecular data
| Amino acid sequence | His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp |
|---|---|
| Molecular formula | C164H252N44O55S |
| Molecular weight | 3752.1 g/mol |
| PubChem CID | 16139605 |
| FDA UNII | 7M19191IKG |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
Studies
- [Review of real-life teduglutide experience]
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support
- Teduglutide for pediatric short bowel syndrome patients
- Teduglutide for the treatment of short bowel syndrome - a safety evaluation
- Teduglutide for treatment of adult patients with short bowel syndrome
Research statistics
339 PubMed publications · 47.3% human clinical research · 41 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Teduglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
—
Teduglutide side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Teduglutide: frequently asked questions
What is Teduglutide?
Recombinant analog of glucagon-like peptide-2 approved for adults and children with short bowel syndrome who depend on parenteral support. It is the only approved peptide acting specifically on intestinal mucosal growth.
How does Teduglutide work?
Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
Is Teduglutide FDA approved?
Yes. Teduglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the amino acid sequence of Teduglutide?
Teduglutide has the sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp, giving a chain of 33 amino acids. Its molecular formula is C164H252N44O55S.
What peptides are similar to Teduglutide?
Compounds most often compared with Teduglutide include Linaclotide, Plecanatide, Larazotide and Secretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Review of real-life teduglutide experience] — Nutr Hosp, 2023External reference
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support — J Pediatr Gastroenterol Nutr, 2023External reference
- Teduglutide for pediatric short bowel syndrome patients — Expert Rev Gastroenterol Hepatol, 2021External reference
- Teduglutide for the treatment of short bowel syndrome - a safety evaluation — Expert Opin Drug Saf, 2018External reference
- Teduglutide for treatment of adult patients with short bowel syndrome — Expert Opin Biol Ther, 2017External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Teduglutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Teduglutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →